JDRF IMPROVING LIVES. CURING TYPE 1 DIABETES.

Australian Type 1 Diabetes Clinical Research Network

Supported by

CICADA INNOVATIONS

Strategic Program for Advancing Research Commercialisation (SPARC) 2024

Request for Applications

Applications Open	31 January 2024
LOI Deadline†	13 March 2024
Full Proposal Deadline*	23 May 2024
Award Notification^	July 2024
Earliest Start	July 2024

* Research Office of each Administering Institution is required to certify applications submitted to JDRF in RMS360 and may have an internal closing time which precedes this deadline

†Deadlines are at 11:59 pm AEST/AEDT.

^Subject to change.

Click Here to Apply

Contents

1. Introduction and Purpose

The JDRF Australian Type 1 Diabetes Clinical Research Network (T1DCRN) provides a national framework to support the most promising type 1 diabetes (T1D) research and clinical trials in Australia. The T1DCRN has a strong track record of supporting outstanding pre-clinical research activities that have made stellar contributions to our understanding of T1D pathogenesis and in advancing translation of basic research towards clinical care.

However, JDRF recognises that there remain significant barriers in translating promising pre-clinical research into the early-stage clinical development of technologies, due to the high risk of failure, combined with a significant increase in capabilities and resources required to prepare for the clinical development stage. At the same time, the commercialisation opportunity of such research in the pre-clinical stage must be validated in-depth, in order to decrease the significant risk of failure, before pursuing the clinical development.

Recognising the widespread lack of commercialisation experience among T1D researchers, and the limited financial and technical support dedicated by funding bodies and industry partners to the T1D space in the pre-clinical stage, the purpose of this ***Request for Applications (RFA) "Strategic Program for Advancing Research Commercialisation (SPARC) 2024"*** are to:

- Identify projects that address a clearly articulated, global unmet need for the diagnosis, prevention, treatment or management of T1D, and have a high potential for commercialisation.
- Foster multidisciplinary collaboration between research teams, funding bodies, industry and the T1D community.
- Specifically support high potential projects to prepare for or enter into the early clinical stage with a shared understanding among the stakeholders of a possible commercialisation pathway, in order to make a positive impact for the T1D community.

The SPARC 2024 RFA solicits proposals from investigators affiliated with Australian institutions with the aim of funding projects in high-impact areas of T1D research. Research projects that clearly articulate potential for a significant benefit to people with T1D.

JDRF Australia in collaboration with Cicada Innovations, Australia's leading commercialisation focused incubator for deep tech companies, will work alongside the research teams to increase their commercial capability and introduce relevant funding, industry, clinical, community and government stakeholders in the process to accelerate their commercial pathway.

Successful Awardees of the SPARC 2024 grants will gain access to a specialised mentoring and capability building Program that has been designed to offer a commercially-driven framework aimed at expediting the advancement of projects ultimately leading them closer to the goal of commercialisation. The Program will be curated by seasoned experts in the field of early research commercialisation. Its comprehensive implementation will span the entire duration of the Award, ensuring that participants receive ongoing guidance and support.

Awardees will engage in purposeful collaboration with commercialisation experts, funding and industry partners, in order to further validate their research, its commercial potential,

refine a possible pathways to impact in clinical setting, and the goal to strive toward the development stage, with a high probability to receive follow-on funding and industry interest.

The Program will support high-potential projects guiding them towards or facilitating entry into the early clinical stage. Establishing a shared understanding among stakeholders regarding the potential commercialisation pathways and how to navigate them. However, it's important to note that this grant does not guarantee specific commercialisation outcomes; rather, it is designed to recognise and support promising research.

2. Objectives and Scope

The key objectives of SPARC 2024 are to:

i. Enhance and broaden the commercialisation skill set and knowledge base of Australian researchers. This will be achieved through providing training, mentoring, and network development, contributing to the long-term growth and capability of Australian type 1 diabetes research and the T1DCRN.

ii. Provide funding and specialised knowledge to enable and expedite the translation of research with commercial potential into novel diagnosis, prevention, treatment or management of T1D, ultimately benefiting people living with T1D.

This RFA aims to support proposals with a strong emphasis in translation and commercialisation where the end goal is to prevent or reduce the burden of T1D. In addition, it aims to nurture talent and collaboration, and improve overall translatability of T1D research findings.

To be able to obtain such support, prospective proposals must align with the following criteria:

2.1 Support Research Commercialisation

- Investigating the potential impact of existing data, including from or different disease areas or use cases, and establishing its validity for the T1D field.
- Extending existing knowledge into a new and distinct area or application of high unmet need and commercial potential.
- Small-scale exploratory implementation and/or validation studies to prove a technology or solution could be commercially viable in order to de-risk future investment in the approach.
- An application of an existing approach from the research outside the field of T1D and directed to illuminate scientific exploration in T1D.

2.2 Nurture Talent and Collaboration

Attract and retain talent of highest quality to T1D research commercialisation, and facilitate multidisciplinary, Australian and international collaboration between:

- Early to mid-career researchers who are seeking to build their translation and commercialisation capabilities.
- Established investigators already active in the field of T1D who are progressing their work towards a commercialisation pathway.
- Early stage and established biomedical companies, conducting research with a strong potential for impact of this research on the T1D community.

- Investigators from fields other than T1D (e.g. other autoimmune conditions, T2D, oncology, immunology, modelling/data science, applied sciences) interested in validating the commercialisation potential and applicability of their research outcomes in T1D.
- Investigators aiming to advance critical pre-clinical stage research with applicability in the T1D space, by undertaking market opportunity validation research, which may lead to commercialisation.
- Investigators aiming to collaborate across multiple Australian states and territories as well as internationally.
- Investigators from or aspiring to collaborate with industry partners (e.g. small biotech and pharmaceutical companies).
- Investigators from or aspiring to collaborate with clinicians and the T1D community.

2.3 Improve Translatability

- Research projects identified as being at an early development stage must have a strong focus and clearly articulated strategy on the translatability of the proposed study to impact people living with T1D.
- Studies using pre-clinical animal models should clearly articulate relevance to humans. Where possible the use of human bio-specimens and/or existing clinical databases, data networks and repositories should be considered.
- Research may present data and findings from other disease types as first use cases, but it must establish a strong, evidence-based link and show applicability to T1D. The need for a specific focus and translation for T1D must be incorporated in the proposal.
- This RFA will focus on attracting talented new investigators from within and outside of the field of T1D as well as embracing experienced investigators in T1D to drive promising early research towards the clinical phase of research translation.
- Proposals submitted are encouraged to include at least one experienced commercialisation or industry expert, who can be from outside of the field of T1D, and must also include an early to mid-career researcher in the leadership group. Each proposal must nominate one member of the multidisciplinary team as the lead in driving the commercialisation of the research project.
- This RFA encourages submissions from projects that have clinicians or clinician scientists as part of the research team.
- This RFA also aims to create collaborative projects between Australian and international investigators to leverage domestic and international expertise and resources to advance T1D research.

3. ELIGIBILITY

All proposals submitted in response to this RFA must demonstrate that they meet the following eligibility criteria.

i. Principal Investigators (PI) and Co-PIs must hold Ph.D., M.D. or an equivalent academic degree to be eligible to apply for this Award. PIs must be affiliated with an Australian university, hospital, research institute, or other comparable institutions which may include a for-profit company.

ii. Applications must be submitted by an Australian institution or a for-profit entity affiliated with the PI. Co-PIs and/or other collaborators may be affiliated with institutions/entities outside of Australia.

iii. The application must involve collaboration with team members from at least one research organisation separate to and independent of the organisation of the lead Principal Investigator; or at least one industry partner.

iv. Early to mid-career researchers (EMCRs) should also be included in the leadership group to provide opportunity for the EMCRs to develop their leadership experience and build commercialisation capabilities.

v. At least one experienced researcher or subject matter expert from outside of the field of T1D must be included to bring capacity and knowledge from other areas that will benefit the field as well as the proposal.
   - Researchers from outside the T1D field are defined as individuals who have not previously held a substantial T1D-related national or international research grant.
   - Subject matter experts are defined as a person providing substantial expertise, knowledge and skills that are likely to increase the chances of the project to progress towards commercialisation.

vi. There are no citizenship requirements for this program however, the Principal Investigator must be eligible to work in Australia for the length of the proposed project. To assure continued excellence and diversity among applicants and awardees, applications are welcomed from individuals with disabilities, and members of minority groups underrepresented in the Australian T1D research landscape.

4. Exclusion Criteria

4.1 Duplication of research

If at any time during the assessment process JDRF or the review panel deems the objectives of a proposal to either duplicate or significantly overlap with the objectives of a current or planned project (in Australia or overseas) the proposal will be excluded from further consideration.

4.2 Applications not suited for this RFA

If at any time during the review process JDRF decides that an application falls within one of the following exclusion criteria the application will be deemed ineligible and will be excluded from further consideration:

i. Applications that lack a clearly articulated vision of steps to translation, accepting that the endpoint of this vision may extend beyond the funding period supported by this scheme, and that by definition early-stage projects will contain inherent risk and may have go/no-go decision points. Examples of endpoints include (but not limited to) eventual commercialisation, changing health care practice, implementing a new approach to imaging, identifying biomarkers, or identifying aetiological factors

ii. Applications that describe exploratory blue-sky research purely for the acquisition of data

5. Application Process

All submissions are to be made using JDRF's online grants management portal RMS360 (http://jdrf.smartsimple.us, see User Guide for details). Applicants are required to login to RMS360 to access supporting documents and templates.

Information submitted is collected, stored and shared in accordance with the JDRF T1DCRN policies on protecting Privacy and managing Conflict of Interest.



The application process will involve two stages.

Stage 1: Letter of Intent (LOI)

i. **Proposal Synopsis**
(2 pages maximum, use template) Summary outlining the area of research, the unmet need in clinical, personal and societal context, main objectives of the project, key personnel and institutions, and check for eligibility.

ii. **Research Commercialisation Plan**
(2 pages maximum excluding references, use template) that provides the following information:
- Impact for the T1D community of the proposed research, clearly articulating the identified unmet need.
- Any existing data and evidence to support the potential impact of addressing the unmet need with the proposed research.
- Advantages over alternative approaches to address the current unmet need.
- Description of research design and methods.
- Milestones towards clinical development, future plans, including IP position, commercialisation opportunity, development strategy and possible partnerships provided the research project reaches its milestones.
- Projected timeline of deliverables.

iii. **Bio-sketch**
(4 pages maximum, use template) of key members of the project team must be provided. Applicants must demonstrate relevant expertise and must have the ability to lead and perform proposed activities.

iv. **Indicative Budget:** A high level budget for the proposed research or project.

Stage 2: Full Proposals

Shortlisted LOIs will be invited to submit full proposals. In addition to the materials submitted in the LOI the following information will be required in the full proposal.

i. **Detailed Research Commercialisation Plan,** elaborating on the proposal outlined in the LOI, and addressing limitations identified by JDRF or the expert review panel.

ii. **Detailed Budget and Justification**: A detailed budget with a clear costing model and justification for use of funds.

iii. **Letters of Support**: It is expected that the letter is prepared on an official letterhead from all institutions and entities involved. The LoS should be signed by the respective Executive/Department/School Head or their equivalent. Its purpose is to convey the following information:
- The institution or entity's alignment with the proposed research.
- Details of each cash or in-kind contribution (e.g., personnel, training, equipment, resources) including value in AUD where appropriate.
- How will the relationship with the project be supported beyond this funding period for eventual realisation of its benefit.

iv. **Data Management Plan:** that outlines the strategies for collecting, storing, protecting, and sharing research data. The plan should be detailed enough to provide a clear understanding of how data will be handled throughout the research project, ensuring integrity and compliance in pursuit of commercialisation.

At each stage JDRF will check applications for compliance with eligibility (Sections 3 and 4). A review panel of national and international experts will then assess the submissions for the quality and originality of the proposed research and its potential to advance knowledge and opportunities for T1D research and clinical care as well as its relevance to the mission of JDRF and the T1DCRN.

The reviewers will assess proposals through a scoring system based on the Selection Criteria outlined in Section 6. Scoring of application is done individually by each expert reviewer, and any reviewer with a conflict of interest is excused from scoring on a specific proposal. Only the highest-quality, highest impact Projects will be invited to proceed to a Full Application. These applicants will be provided with written critiques from the reviewers which must be addressed in their Full Application. Further information about this process will be provided to applicants who are invited to submit a Full Application.

Applicants may be invited to an interview with a member of the assessment panel to provide further clarification to questions from the reviewers, before submitting these to the full review panel in writing. Applicants also have the option to request a call with a JDRF Australia representative, to seek clarification before submitting their final full application.

The Panel will consider the merit of the applications and provide appraisal of the merit and ranking of the application against the selection criteria. The JDRF Australia Board has the responsibility to approve grants for funding and allocation of the final budget.

JDRF or the review panel may suggest changes to the research and project plan and budget at any stage during the review process.

Successful awardees will be notified, and a Funding Agreement will be executed with the applicants' administering institution. After a grant is awarded, JDRF monitors the progress of the Project.

6. Selection Criteria

Submissions will be assessed by an independent panel for merit based on the following selection criteria. Applicants must ensure that adequate information is provided in a clear and manner to allow the reviewers to assess their proposals against each of the weighted selection criteria:

- **Significance and Impact (30%)**
  - How significant will the project's impact be on advancing T1D research towards clinical practice and/or improving lives of people with T1D? LOIs should address the current and future unmet need, its current impact on T1D, and outlining how the research could lead to a solution or technology that could address the unmet need globally. The application should identify critical barriers to progress and articulate the impact the proposed project will have in the field.

- How the proposed project will improve scientific knowledge, diagnostic capability, and/or clinical practice.
- Clear focus on articulating the potential for translation and commercialisation towards clinical care including clinical co-design, validation with people living with T1D, clinicians and possible payers, future clinical trials and development of assays for early diagnosis of T1D, industry and other partnerships.
- How the project team are planning to expand their skill sets, knowledge base and overall capacity to translate Australian T1D research.

- **Innovation and Novelty (20%)**
  - Extent to which the proposed work is original and innovative, supported by convincing argument with appropriate citations.
  - How the proposed work challenges and seeks to shift current research or clinical practice, this may include clearly articulating how research outside the T1D context could be translated to T1D.
  - Scope of novel concepts, approaches or methodologies to be developed or used, and any advantage over existing alternatives.
  - Scope of any refinements or improvements of existing concepts, approaches or methodologies.

- **Study Design and Research Commercialisation Methods (20%)**
  - Quality of the overall strategy, methodology, and analyses to be used to accomplish the specific aims of the project.
  - Clarity of how the data will be collected, analysed, and interpreted as well as the scope of resource sharing.
  - Foresight of potential problems, alternative strategies and benchmarks for success anticipated to achieve the aims.

- **Team Expertise and Environment (20%)**
  - Expertise of the PI and Co-PIs and core members of the team (refer to selection criteria).
  - Level of collaboration, cross-disciplinary expertise.
  - Provision to institutional resources, infrastructure and other support mechanisms.

- **Feasibility (10%)**
  - Appropriateness of proposed timeline and budget.
  - Likelihood of obtaining ethical approval if needed.
  - Potential and clear plan for future steps including protection of Intellectual Property, obtaining larger funds from other sources and progressing to end-users.

7. FUNDING

The SPARC 2024 Awards will provide funding for up to $150,000 in total for a period of up to 12 months, subject to sufficient funding being available and continued satisfactory progress of the study. It is expected that a maximum of five (5) Grants will be awarded. The level of funding for individual projects will vary depending on the scope and overall objectives of the project.

For successful projects with budgets exceeding $150,000, there is an expectation to make up for the additional funds from other sources.

Budgets must be well justified and strongly commensurate with project scope.

At the LOI stage, budget amounts must be indicative of size and scope of the project. Detailed budgets will be required only in the event where the application progresses to full submission. JDRF or/and the reviewers reserve the right to recommend levels, duration and scope of funding which may differ from those requested in the application.

Please note: Grants awarded by JDRF through the T1DCRN are listed on the Australian Competitive Grants Register. As such, indirect costs can be recovered through Research Block Grants funding. JDRF will not provide funding for indirect costs including basic facilities and equipment, organisational overheads and/or infrastructure costs. These must not be included in the budget request.

8. Submission Instructions and Checklist

8.1 Instructions

Applications must be submitted online using JDRF's online grants management system RMS360 (http://jdrf.smartsimple.us). Submission instructions and FAQs are available here. *Please contact JDRF Administrative Staff if you require assistance.*

Information submitted as part of the application is collected and stored in accordance with the JDRF Australia's Privacy Policy. All parties involved in or associated with an application must declare at the date of submission any Conflict of Interest that exists or is likely to arise in relation to any aspect of the application.

JDRF will only consider complete applications that meet Application formatting requirements as required in the templates provided in RMS360. Scanned documents are not acceptable.

A submission is complete if:

- It includes all the documents listed in the submission checklist below.
- All mandatory fields in RMS360 are complete.

8.2 Submission Checklist

LOI

Item	Template provided	Instruction for RMS360
☐ Proposal Synopsis	Yes	Upload in "Additional Attachments" tab
☐ Research Commercialisation Plan	Yes	Upload in "Proposal Research Plan" tab.
☐ Bio sketches	Yes	PI/Co-PIs bio sketches should be uploaded to their investigator's profile. Bio-sketches will append to the application.

		Key Personnel bio sketches upload in "Additional Attachments" tab.
☐ Indicative Budget	No	Complete "Budget" tab

Full Proposal

Item	Template provided	Instruction for RMS360
☐ Detailed Research Commercialisation Plan	Yes	Upload in "Proposal Research Plan" tab.
☐ Detailed Budget	Yes	Complete "Budget" tab, and Upload spreadsheet in "Additional Attachments" tab
☐ Budget Justification	Yes	Upload in "Additional Attachments" tab
☐ Data Management Plan	No	Upload in "Additional Attachments" tab.
☐ Letters of Support	No	Upload in "Additional Attachments" tab.
☐ Supplementary Information (if requested)	No	Upload in "Additional Attachments" tab.

9. Contractual Requirements

9.1 Funding Agreement

This funding will be provided by JDRF administered by the recipient's institution. The award recipient will be required to sign a Funding Agreement with JDRF Australia (Agreement), which will be provided to the administering institution after a proposal has been recommended for funding.

The Funding agreement stipulates that the Project's Intellectual Property has been or is intended to be protected (if applicable); that all project relevant Intellectual Property is clearly identified, and the research team has the rights to, or is working towards securing the rights to commercialise the Intellectual Property.

JDRF has no obligation in respect of this RFA including any funding, unless and until JDRF and the successful applicant(s) have executed the formal Agreement. JDRF expects the Agreement to be executed prior to the grant start date, unless otherwise agreed by JDRF. The Agreement template will include, but is not limited to, the following:

i. A payment schedule dependent upon the achievement of project milestones. JDRF will determine such milestones to be included in the Agreement in consultation with the relevant Investigators.

ii. An obligation to comply with all relevant JDRF Policies as further detailed in the Agreement.

JDRF reserves the right to require changes to the Agreement template to address specific needs and circumstances of an application.

9.2 Consent to Combine Applications

The objectives of this RFA and the T1DCRN emphasise collaboration and encourage research that presents the greatest benefit to the T1D community. After the review of the LOIs, shortlisted applications from separate investigators may be invited to combine their applications into a single Full Application submission where such collaboration is deemed necessary to maximise benefit and avoid overlap.

In submitting an LOI in response to this RFA, applicants consent to information about their application being shared with other applicants for this purpose and acknowledge they may be asked to combine their application with another applicant as a condition of being invited to submit a Full Application. Applicants will be informed about this possibility prior to sharing any information, providing the opportunity for them to withdraw their application if required.

9.3 Consent to Co-funding

JDRF actively seeks co-funding opportunities with other funding bodies and partner institutions. In submitting an LOI in response to this RFA applicants consent to information about their LOI being shared with other funding bodies that are specifically interested in supporting the research and related activities generated through the T1DCRN.

9.4 Consent to Collaboration with industry and community partners

The aim of the Grant is to support the research team in validating the commercial potential of their research to increase the likelihood to receive funding for the clinical development phase and potential interest by industry partners to support the full translation of the research into clinical technologies and solutions. JDRF Australia intends to match relevant stakeholders with the research team, with the team's consent, in order to support the research team reaching their translation and commercialisation milestones.

9.5 Data and Resource Sharing

All applicants invited to Full Application will be required to submit a Data Sharing Plan. For more information please refer to the T1DCRN Data and Biosample Sharing Policy.

JDRF acknowledges that resource sharing plans will differ according to the types of data and biosamples collected and does not prescribe the exact content or format. JDRF requests that at a minimum the core elements outlined in the Data Sharing Plan template in Appendix A of the JDRF Australian T1DCRN Data and Biosample Sharing Policy are considered.

9.6 Publications and Open Access

The T1DCRN strongly advocates for the prompt publication and broad dissemination of research outcomes and materials developed with its funding, in alignment with the NHMRC Open Access Policy. However, recognising the critical importance of Intellectual Property (IP) protection in commercialisation, award recipients are expected to carefully navigate these requirements. While complying with the Open Access Policy, recipients must also implement strategies to safeguard sensitive IP integral to their project's commercial potential.

This includes timely filing for patents or other appropriate forms of IP protection before public disclosure. Our program will assist recipients in balancing these dual objectives: ensuring open access to research findings and materials where feasible, while also securing and managing IP rights effectively.

10. Program Contacts

If you would like to discuss the alignment of your proposal to this RFA, please consult:

Auvro Mridha, PhD	**Dorota Pawlak, PhD**	**Katja Beitat, PhD**
Scientific Program Manager	Chief Scientific Officer	Head of Healthtech
JDRF Australia	JDRF Australia	Cicada Innovations
☎ 0412 758 022	☎ (02) 8364 0206	☎ 0403 710 192
💻 amridha@jdrf.org.au	💻 dpawlak@jdrf.org.au	💻 katja@cicadainnovations.com

If you have enquiries relating to using RMS360, please consult:

Serena Radano

Grants Administration Officer

JDRF Australia

☎ (02) 8364 0243

💻 sradano@jdrf.org.au

APPENDIX: ABOUT JDRF AUSTRALIA AND THE T1DCRN

Type 1 diabetes (T1D) is a serious, chronic autoimmune condition that affects over 120,000 Australians[1]. T1D is classically characterised by a sudden and pronounced onset in children, adolescents and young adults, requiring immediate and life-long dependence on exogenous insulin due to autoimmune destruction of pancreatic beta cells. It is now recognised that T1D initially progresses through a silent asymptomatic phase characterised by the persistence of circulating islet autoantibodies. This asymptomatic phase can last for months or years, until diagnosis of clinical T1D requiring carefully titrated exogenous insulin therapy[2]. Underlying genetic predisposition or/and delayed trigger factors as well as the role of stressed and sick beta cells in necessitating an immune reactive pathway, are yet to be fully understood. Clinical manifestations and the disease evolving epidemiology of T1D globally remain overwhelming and unresolved.

JDRF is the world's biggest non-profit funder of T1D research with the ultimate goal to find a cure for T1D. Until a cure is found, our focus is on advances that ease the burden for those living with the disease. The key to treating, preventing, and ultimately curing T1D is the swift translation of Australian and global basic science and applied research outcomes into treatments and technologies that work effectively in people. Australian T1D research ranks highly on a global scale[3], but adoption into clinical care remains a challenge. Overcoming this challenge requires an important step out of the laboratory and the translation of research into human trials.

The Australian Type 1 Diabetes Research Clinical Research Network (T1DCRN), a JDRF initiative, is a national framework that supports the most promising T1D research and clinical trials. The network was informed by The Australian Type 1 Diabetes Research Agenda, developed through a broad consultation process with researchers, clinicians and T1D community representatives.

The T1DCRN was launched in June 2010, initially through a $5 million, four-year grant from the Australian Government through the Department of Health and Ageing. In 2014, a further $35 million over five years was provided by the Australian Government via the Australian Research Council.

The T1DCRN has established a highly successful research network bringing together world-class researchers, the T1D community, industry and international partners to answer critical T1D clinical research questions, with a strong focus on benefitting people living with T1D. In addition to fostering the most outstanding T1D research talent, the T1DCRN attracts exceptional scientists from other disciplines to broaden the scope of T1D research in Australia.

To date, the T1DCRN has invested $58M in Australian research and attracted over $94M of financial leverage. T1DCRN initiatives have supported more than 450 researchers across 70 funded projects, connecting approximately 7,000 Australians with the latest research, treatments and technologies[4]. The sharp focus on benefitting people living with T1D is a

[1] jdrf.org.au

[2] Diabetes Care Oct 2015, 38 (10) 1964-1974.

[3] The Australian Research Impact Analysis

[4] JDRF Australia T1DCRN: a decade of impact

unique dimension of the T1DCRN and the community-centric approach provides a platform to accelerate therapies and amplify research impact.

In 2019, the Australian Government committed a further $25M to extend the T1DCRN for an additional five years to 2024. This new investment aims to build on prior achievements and increase the impact of T1DCRN via expansion of its scientific priorities. The new phase of the T1DCRN aims to:

- Increase the volume and impact of Australian T1D clinical research, while investing in large-scale prevention and screening initiatives
- Support “bench to bedside” research and ensure researchers have the required supporting tools and policy environment, and
- Nurture current and future research leaders in T1D while attracting bright new talent.